Introdução à Medicina Turma 12
description
Transcript of Introdução à Medicina Turma 12
Introdução à MedicinaTurma 12
Authors: Melo AR, Pinto C, Alves FC, Pereira JP, Garcia M, Gouveia P, Pinto RJ, Cavaco TC, Valente TAuthor’s contact: [email protected]: Professor Tiago Jacinto
IntroductionIntroduction
Turma 12
There is still no clear definition of asthma control: the criteria used in its evaluation the criteria used in its evaluation varies from study to study varies from study to study (Reddel H et al. American Thoracic
Society Documents 2008)
American Thoracic Society – 2006 List of outcome measures:
- Baseline- During the study
Turma 12
Both on baseline characteristics baseline characteristics and on the assessment of the treatment effect on current assessment of the treatment effect on current clinical controlclinical control: Symptom free daysRelievers useComposite scores (He Q. Ofqual 2009)
Quality of life (LJ Bilingham et al, Health Technology Assessment 1999)
Baseline characteristicsBaseline characteristics: Pre-BD Fev 1 (Spirometry for health care providers)Pos-BD Fev 1 (Spirometry for health care providers)
Assessment of the treatment effect on current Assessment of the treatment effect on current clinical controlclinical control:Exacerbation within last 1-4 weeks
Turma 12
Research questionResearch question
Turma 12
MAIN RESEARCH QUESTION - Are randomized controlled trials that assess inhaled asthma therapy drugs using the minimum outcome measures recommended by the American Thoracic Society both on baseline and during the trial?
Is there any relation between pharmaceutical industry sponsorship and outcome measures taken?
Turma 12
AimsAims
Turma 12
Determine if RCTs are using the minimum set of outcome measures recommended.Analyze which measures are used the most.Understand the evolution of measures taken:
○ Through time;○ Before and after the ATS’s guideline (2006).
Determine if there is a relation between pharmaceutical industry sponsorship and outcome measures taken.
Turma 12
Methods and ParticipantsMethods and Participants
Turma 12
Data collection
"Asthma” - clinicaltrials.gov databaseInterventional studies phase IIIClosed studies with results12 years and older participants
○ 61 articles
"Asthma” - clinicaltrialsregister.eu databaseInterventional studies phase IIICompleted studies12 years and older participants
○ 81 articles
Total of 142 articles foundTurma 12
Eligibility criteria:
Randomized controlled trial phase III; Asthma; English language; Pos 1980 (included); 12 years and older; Medication: beta-2-agonists and inhaled
corticosteroids.
Turma 12
Flowchart
Turma 12
n=61 n=81
Inclusions
Turma 12
17 trials included5 from clinicaltrials.gov12 from clinicaltrialsregister.eu
Variables to exam
Measures taken
Sponsoring by pharmaceutical industry
Turma 12
Turma 12
ResultsResults
• Articles’ Graphs
-Number of Recommended Outcome Measures used by each article according to time and database it was searched
Turma 12
American DatabaseEuropean Database
n =17
The line represent the Cut-off
-Recommended Outcome Measures’ Frequency in articles included
Turma 12
n=11
• Pharmaceutical Industry Sponsorship
There is not enough data to analyse the influence of pharmaceutical industry.Only 2 in 17 articles were not sponsored
Turma 12
Statistical Analysis
Turma 12
Variable examined: number of recommended outcome measures used
T-test to compare databases○ p= 0,002 (µ=5 , µ=2)
T-test to compare before/after 2007○ p= 0,018 (µ=5 , µ=2)
Turma 12
Discussion and ConclusionDiscussion and Conclusion
Discussion and Conclusion
Turma 12
There is no evidence that the number of recommended outcome measures taken by articles has increased after 2007.
It seems that the ATS guideline is not being followed
No conclusions concerning the influence of pharmaceutical industry sponsoring
ReferencesReferences
Turma 12
[1] - Bateman E, B.L., Cruz A, FitzGerald M, Haahtela T, Levy M, O'Byrne P, Ohta K, Paggario P, Pedersen S, Soto-Quiroz M, Wong G, executive committee. Becker A, Lemanske R, Pedersen S, Sly P, Soto-Quiroz M, Wong G, Zar H, pediatric writting group. Pocket Guide for Asthma Management and Prevention in Children 5 years and younger. GINA - Global Initiative for Asthma . 2009.
[2] - Masoli M, Fabian D, Holt S, Beasley R. Global Burden of Asthma. GINA - Global Initiative for Asthma . 2006.
[3] - Frampton GK, Shepherd J. Patient-reported outcomes in clinical trials of
inhaled asthma medications: systematic review and research needs. Qual Life Res. 2010 Oct 14.
[4] - Fromer L. Managing asthma: an evidence-based approach to optimizing
inhaled corticosteroid treatment. Department of Family Medicine, UCLA School of Medicine (Los Angeles, USA). Souther Medical Journal. 2010 Oct; 103(10): 2-3
[5] – The Diagnosis and Treatment of Adult Asthma. Best Practice Evidence-
based Guideline (Wellington, New Zealand). New Zealand Guidelines Group (NZGG).2002 Sep. 1-3.
Turma 12
[6] - Asthma Management Handbook. National Asthma Council Australia(South Melbourne). 2006
[7] - Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, Casale TB, Chanez P, Enright PL, Gibson PG, de Jongste JC, Kerstjens HA, Lazarus SC, Levy ML, O'Byrne PM, Partridge MR, Pavord ID, Sears MR, Sterk PJ, Stoloff SW, Sullivan SD, Szefler SJ, Thomas MD, Wenzel SE. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. American Journal of Respiratory and Critical Care Medicine. 2009 Jul 1;180(1): 59-99
[8] - He Q. Estimating the Reliability of Composite Scores. Ofqual. 2009
Dec. 10: 1
[9] - Billingham LJ, Abrams KR, Jones DR. Methods for the analysis of quality-of-life and survival data in health technology assessment. Health Technology Assessment (Winchester, England). 1999;3(10):1-152.
[10] – Spirometry for health care providers. Global Initiative for Chronic Obstructive Lung Disease (GOLD). 1-2
Turma 12